What is Spirair?
Spirair operates at the intersection of medical innovation and clinical efficiency, focusing on the development of minimally invasive tools designed for ear, nose, and throat (ENT) specialists. Founded by Stanford Biodesign and Innovation fellows, the company addresses critical gaps in current treatment algorithms. By prioritizing patient experience and clinical outcomes, Spirair provides practitioners with advanced, easily integrated solutions that facilitate improved respiratory health. The firm's market position is defined by its commitment to evidence-based design and its ability to scale within the competitive landscape of medical device manufacturing.
How much funding has Spirair raised?
Spirair has raised a total of $12.8M across 1 funding round:
Private Equity
$12.8M
Private Equity (2025): $12.8M, investors not publicly disclosed
Key Investors in Spirair
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Spirair?
With the recent influx of capital, Spirair is poised to transition into a phase of rapid commercial expansion and product refinement. The strategic roadmap likely involves scaling manufacturing capabilities to meet growing demand and deepening its footprint within clinical settings. By leveraging this financial backing, the company aims to solidify its role as a leader in ENT innovation, potentially exploring new regulatory pathways and expanding its portfolio of minimally invasive technologies. As the firm matures, the focus will remain on maintaining high-quality outcomes while streamlining the integration of its devices into standard ENT practice, ultimately driving long-term value for stakeholders and patients alike.
See full Spirair company page
